http://dspace.zsmu.edu.ua/handle/123456789/18314 2026-09-11T08:18:46Z 2026-09-11T08:18:46Z Левада, Олег Анатолійович Чабан, О. С. Пінчук, І. Я. http://dspace.zsmu.edu.ua/handle/123456789/25833 2026-09-09T06:27:28Z 2014-01-01T00:00:00Z

Название: Епідеміологічні аспекти судинної деменції: стан проблеми за останні 5 років Авторы: Левада, Олег Анатолійович; Чабан, О. С.; Пінчук, І. Я.

2014-01-01T00:00:00Z Levada, O. A. Cherednichenko, N. V. Trailin, A. V. Troyan, O. S. Левада, Олег Анатолійович Троян, Олександра Сергіївна http://dspace.zsmu.edu.ua/handle/123456789/25831 2026-09-09T06:19:45Z 2016-01-01T00:00:00Z

Название: Plasma Brain-Derived Neurotrophic Factor as a Biomarker for the Main Types of Mild Neurocognitive Disorders and Treatment Efficacy: A Preliminary Study Авторы: Levada, O. A.; Cherednichenko, N. V.; Trailin, A. V.; Troyan, O. S.; Левада, Олег Анатолійович; Троян, Олександра Сергіївна Аннотация: Decreased levels of brain-derived neurotrophic factor (BDNF) are assumed to play a crucial role in the pathophysiology of mild neurocognitive disorders (MNCDs). In this study, we compared plasma BDNF levels (at baseline and after two months of treatment with escitalopram) in patientswith the main types ofMNCDs and normal controls. 21 patients met the DSM-5 diagnostic criteria for possibleMNCDdue toAlzheimer’sdisease (MNCD-AD); 22patients fulfilledthediagnostic criteria for subcortical vascularMNCD (ScVMNCD) according to Frisoni et al. (2002) and neuroimaging-supported probable diagnosis of vascular MNCD according to DSM-5; 16 subjects entered control group. At baseline, we detected lower BDNF levels in bothMNCDgroups, which was significant only in subjects with MNCD-AD. Moreover, plasma BDNF level of 21160 pg/mL showed high sensitivity (94%) to discriminate patients with MNCD-AD. Decreased plasma BDNF highly correlated with the severity of memory impairment and total MMSE score inMNCD-AD group. Escitalopram treatment in patients withMNCD-AD or ScVMNCD led to an increase of plasma BDNF concentrations and as a result to a decrease of cognitive, depressive, and anxiety symptom severity. In conclusion, plasma BDNF might be a reliable biomarker for the validation of MNCD-AD diagnosis and treatment efficacy.

2016-01-01T00:00:00Z Troyan, A. S. Levada, O. A. Троян, Олександра Сергіївна Левада, Олег Анатолійович http://dspace.zsmu.edu.ua/handle/123456789/25830 2026-09-09T06:14:06Z 2020-01-01T00:00:00Z

Название: The diagnostic value of the combination of serum brain-derived neurotrophic factor and insulin-like growth factor-1 for major depressive disorder diagnosis and treatment efficacy Авторы: Troyan, A. S.; Levada, O. A.; Троян, Олександра Сергіївна; Левада, Олег Анатолійович Аннотация: Background: Last decades of psychiatric investigations have been marked by a search for biological markers that can clarify etiology and pathogenesis, confirm the diagnosis, screen individuals at risk, define the severity, and predict the course of mental disorders. In our study, we aimed to evaluate if BDNF and IGF-1 serum concentrations separately and in combination might be used as biomarkers for major depressive disorder (MDD) diagnosis and treatment efficacy and to evaluate the relationships among those proteins and clinical parameters of MDD. Methods: Forty-one MDD patients (according to DSM-5) and 32 healthy controls (HC) were included in this study. BDNF and IGF-1 serum concentrations, psychopathological (MADRS, CGI) and neuropsychological parameters (PDQ-5, RAVLT, TMT-B, DSST), functioning according to Sheehan Disability Scale were analyzed in all subjects at admission and 30 MDD patients after 8 weeks of vortioxetine treatment. Correlational analyses were performed to explore relationships between BDNF and IGF-1 and clinical characteristics. AUC-ROCs were calculated to determine if the value of serum BDNF and IGF-1 levels could serve for MDD diagnosis.

2020-01-01T00:00:00Z Levada, O. A. Troyan, A. S. Левада, Олег Анатолійович Троян, Олександра Сергіївна http://dspace.zsmu.edu.ua/handle/123456789/25829 2026-09-09T06:06:15Z 2018-01-01T00:00:00Z

Название: Poststroke Depression Biomarkers: A Narrative Review Авторы: Levada, O. A.; Troyan, A. S.; Левада, Олег Анатолійович; Троян, Олександра Сергіївна Аннотация: Poststroke depression (PSD) is the most prevalent psychiatric disorder after stroke, which is independently correlated with negative clinical outcome. The identification of specific biomarkers could help to increase the sensitivity of PSD diagnosis and elucidate its pathophysiological mechanisms. The aim of current study was to review and summarize literature exploring potential biomarkers for PSD diagnosis. The PubMed database was searched for papers published in English from October 1977 to December 2017, 90 of which met inclusion criteria for clinical studies related to PSD biomarkers. PSD biomarkers were subdivided into neuroimaging, molecular, and neurophysiological. Some of them could be recommended to support PSD diagnosing. According to the data, lesions affecting the frontal-subcortical circles of mood regulation (prefrontal cortex, basal nuclei, and thalamus) predominantly in the left hemisphere can be considered as neuroimaging markers and predictors for PSD for at least 1 year after stroke. Additional pontine and lobar cerebral microbleeds in acute stroke patients, as well as severe microvascular lesions of the brain, increase the likelihood of PSD. The following molecular candidates can help to differentiate PSD patients from non-depressed stroke subjects: decreased serum BDNF concentrations; increased early markers of inflammation (high-sensitivity C-reactive protein, ferritin, neopterin, and glutamate), serum pro-inflammatory cytokines (TNF-a, IL-1b, IL-6, IL-18, IFN-g), as well as pro-inflammatory/anti-inflammatory ratios (TNF-a/IL-10, IL-1b/IL-10, IL-6/IL-10, IL-18/IL-10, IFN-g/IL-10); lowered complement expression; decreased serum vitamin D levels; hypercortisolemia and blunted cortisol awakening response; S/S 5-HTTLPR, STin2 9/12, and 12/12 genotypes of the serotonin transporter gene SLC6A4, 5-HTR2a 1438 A/A, and BDNF met/met genotypes; higher SLC6A4 promoter and BDNF promoter methylation status. Neurophysiological markers of PSD, that reflect a violation of perception and cognitive processing, are the elongation of the latency of N200, P300, and N400, as well as the decrease in the P300 and N400 amplitude of the event-related potentials. The selected panel of biomarkers may be useful for paraclinical underpinning of PSD diagnosis, clarifying various aspects of its multifactorial pathogenesis, optimizing therapeutic interventions, and assessing treatment effectiveness.

2018-01-01T00:00:00Z